Breaking News

EMD Millipore, Precision Biologics in Process Development Pact

To provide upstream process development from single-use biodevelopment center in France

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

EMD Millipore has entered an agreement with Precision Biologics, Inc. to provide upstream process development services to advance a preclinical monoclonal antibody, NEO-201. The antibody binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian, and pancreatic. EMD Millipore will leverage its Provantage Service offering for biopharmaceutical manufacturing to help customers design and devel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters